Edition:
United Kingdom

CytRx Corp (CYTR.OQ)

CYTR.OQ on NASDAQ Stock Exchange Capital Market

1.75USD
14 Dec 2017
Change (% chg)

$-0.06 (-3.31%)
Prev Close
$1.81
Open
$1.80
Day's High
$1.80
Day's Low
$1.66
Volume
67,037
Avg. Vol
56,960
52-wk High
$5.99
52-wk Low
$1.66

Chart for

About

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue... (more)
No analyst recommendations are available for .

Overall

Beta: 2.34
Market Cap(Mil.): $69.25
Shares Outstanding(Mil.): 165.83
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Cytrx announces new shareholder initiatives

* Cytrx Corporation provides business update and announces new shareholder initiatives

13 Nov 2017

BRIEF-Cytrx reports strategic realignment of clinical development team

* Cytrx announces strategic realignment of clinical development team

06 Nov 2017

BRIEF-Cytrx Corp announces reverse stock split

* Cytrx Corp- ‍1-for-6 reverse​ stock split will become effective as of commencement of trading on Wednesday, November 1, 2017 Source text for Eikon: Further company coverage:

31 Oct 2017

BRIEF-CytRx Corp provides business update and highlights future plans

* CytRx Corp provides business update and highlights future plans

02 Oct 2017

BRIEF-CytRx corp says Glass Lewis & Co recommends CytRx stockholders vote "for" proposed reverse stock split​

* CytRx Corp - proxy advisory firm Glass Lewis & Co. Recommends CytRx Corp stockholders vote "for" proposed reverse stock split​ Source text for Eikon: Further company coverage:

21 Sep 2017

BRIEF-CytRx Corp announces amendment to definitive proxy statement for upcoming special meeting

* CytRx Corp announces amendment to definitive proxy statement for upcoming special meeting

13 Sep 2017

BRIEF-Cytrx reports Q2 loss per share $0.10

* Cytrx corp - ‍cash, cash equivalents and short-term investments of $55.0 million as of june 30, 2017​ Source text for Eikon: Further company coverage:

03 Aug 2017

BRIEF-Cytrx Corp announces Global Strategic License With Nantcell for Aldoxorubicin

* CytRX Corporation announces global strategic license with Nantcell Inc for Aldoxorubicin, an albumin mediated chemotherapeutic

28 Jul 2017

Earnings vs. Estimates